About crovalima b
Complement C5 inhibitor monoclonal antibody
Used for
- Treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and children weighing at least 40 kg.
Usual adult dose
First, 1,000 mg by intravenous infusion on day 1; then 340 mg under the skin on days 2, 8, 15, and 22. From day 29, 680 mg under the skin every 4 weeks.
Usual dose in children
For children weighing at least 40 kg: same schedule as adults. Not established for children under 40 kg.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Headache
- Infusion reactions
Important warnings
- Can cause life-threatening meningococcal and other serious infections.
- Meningococcal vaccination is required before treatment when possible; urgent treatment may need antibiotics.
- Seek urgent care for fever, severe headache, rash, confusion, or other infection symptoms.
- Treatment can increase risk of serious infection from encapsulated bacteria.
Pregnancy
Use only when clearly needed; human pregnancy data are limited. Untreated PNH also poses serious pregnancy risks.
Breastfeeding
It is unknown whether crovalimab passes into breast milk; discuss risks and benefits with a healthcare professional.
Interactions
- Can interfere with some laboratory tests, including assays using the complement pathway.
- Other complement inhibitors may increase infection risks; combined use requires specialist oversight.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.